Drugs / EX103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06021678 | Nov 2021 → Oct 2025 overdue | B-cell non-Hodgkin lymphoma | Guangzhou Excelmab Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EX103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06021678 ↗ |
| Modality | Monoclonal antibody | “bispecific monoclonal antibody that recognizes both CD3 and CD20” NCT06021678 ↗ |